Last reviewed · How we verify
IBI3032 tablets
At a glance
| Generic name | IBI3032 tablets |
|---|---|
| Sponsor | Innovent Biologics Technology Limited (Shanghai R&D Center) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBI3032 tablets CI brief — competitive landscape report
- IBI3032 tablets updates RSS · CI watch RSS
- Innovent Biologics Technology Limited (Shanghai R&D Center) portfolio CI